EQS-Adhoc

Medios acquires Dutch market leader in pharmaceutical compounding services

EQS-Ad-hoc: Medios AG / Key word(s): Mergers & Acquisitions/Expansion Medios acquires Dutch market leader in pharmaceutical compounding services 18-March-2024 / 20:41 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Medios acquires Dutch market leader in pharmaceutical compounding services

Berlin, March 18, 2024 – Medios AG (“Medios”), the leading provider of Specialty Pharma Solutions in Germany, acquires Ceban Pharmaceuticals B.V. ("Ceban"), a fast-growing pharmaceutical compounding platform operating in the Netherlands, Belgium and Spain. With the combination with Ceban, Medios internationalizes its business model and realizes an important step to create a European Specialty Pharma platform. Ceban is expected to generate in 2023 revenue of c. €160 million and an EBITDA after certain adjustments of c. €29 million (EBITDA margin of c. 18%).

Medios acquires a 100% interest in Ceban from funds managed by Bencis. The purchase price consists of a cash component of €235.3 million plus 1.7 million new Medios shares valued at approx. €23.9 million, based on the closing price of the Medios shares in the XETRA trading system of Frankfurt Stock Exchange on March 14, 2024. The new Medios shares held by the Sellers of Ceban will be subject to a hard lock-up of 24 months.

The purchase price is financed by Medios from existing cash and a €200 million committed credit facility. The 1.7 million new shares in Medios will be issued out of authorized capital against contribution in kind without subscription rights for shareholders.

The completion of the transaction is subject to the fulfilment of customary closing conditions and is expected to occur in the second quarter of 2024.

Assuming the completion of the acquisition of Ceban in Q2, Medios expects revenue in the FY 2024 to reach €1.9 to €2.1 billion along with an EBITDA pre¹ of €82 to €91 million, realizing a margin of around 4.3% based on the mean value of the respective revenue and EBITDA pre¹ range.